Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 41

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 41
---
 same talent market; |

| • |     | companies operating in the bio/pharmaceutical industry with similar business and financial profiles; and |

| • |     | companies of similar size, measured by research and development expenditures, number of employees and market capitalization. |

The peer group, supplemented by other sources of competitive pay information, were an important input in establishing compensation levels and structure for fiscal 2024. We target total cash compensation at the market median. The 22 companies in our 2024 peer group are listed below:

| 2024 Peer Group      |     |                          |
| ALX Oncology         |     | Mersana Therapeutics     |
| Aura Biosciences     |     | Monte Rosa Therapeutics  |
| Bicycle Therapeutics |     | PMV Pharmaceuticals      |
| Cullinan Oncology    |     | Poseida Therapeutics     |
| Editas Medicine      |     | RAPT Therapeutics        |
| Foghorn Therapeutics |     | Replimune Group          |
| IDEAYA Biosciences   |     | Stoke Therapeutics       |
| Inhibrx              |     | Sutro Biopharma          |
| Iteos Therapeutics   |     | Tango Therapeutics       |
| Keros Therapeutics   |     | Y-mAbs Therapeutics      |
| Kura Oncology        |     | Zentalis Pharmaceuticals |

Results of 2024 Shareholder Advisory Vote on Named Executive Officer Compensation We hold an annual shareholder advisory vote on named executive compensation. Accordingly, our most recent proposal was held last year and shareholders were asked to approve, on an advisory basis, the 2023 compensation for our named executive officers as reported in our 2024 proxy statement. This say-on-payproposal was approved by over 99.9% of the shares present at the meeting or by proxy and entitled to vote on the matter. The compensation committee viewed the results of the advisory vote as demonstrating broad shareholder support for our current executive compensation program. Given the results of the shareholder advisory vote, and the compensation committee’s ongoing review of our compensation programs, the compensation committee believes that our existing compensation program effectively aligns the interests of the named executive officers with our long-term goals. While the shareholder vote on compensation is advisory in nature, the board and the compensation committee will carefully consider the results of any such vote in future compensation decisions. Elements of Executive Compensation The principal components of compensation for our named executive officers are: (1) annual base salary; (2) short-term